Form 4 for RLAY Relay Therapeutics, Inc.
Accepted 2025-07-01 00:00:00 ET · period of report 2025-06-30 · accession 0000950170-25-092305 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-01 | 2025-06-30 | RLAY | Patel Sanjiv | Pres, CEO, Dir | A - Grant | $2.94 | +5,000 | 826.7K | +0.6% | +$14.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-30 | A | A | 5,000 | $2.94 | 826,667 | D | — | — | (F2) In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025. (F3) Includes 410,560 shares underlying RSUs. |